ReviewMalaria journal2011
Primaquine in vivax malaria: an update and review on management issues.
Review in Malaria journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- In vivo efficacy of anti-malarial drugs against clinical Plasmodium vivax malaria in Ethiopia: a systematic review and meta-analysis.Malaria journal · 2021Pooled it
- Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2020Pooled it
- The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials.International journal for parasitology. Drugs and drug resistance · 2017Pooled it
- Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2015Pooled it
- A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.Malaria journal · 2022Trial
- Article
- Article
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Efficacy of primaquine-chloroquine combination onParasite epidemiology and control · 2026Article
- Design, synthesis, and anti-plasmodial profiling of oxalamide-linked 4-aminoquinoline-phthalimide hybrids.RSC medicinal chemistry · 2025Article
- Enhancing CYP2D6 genotyping with nanopore sequencing to address allele diversity P. vivax malaria elimination.Scientific reports · 2025Article
- Analysis of Severe and Relapse Risks of Imported Malaria in Five Provinces of China.The American journal of tropical medicine and hygiene · 2025Article
- Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.Breast cancer research and treatment · 2024Article
- Article
- Genetic basis and spatial distribution of glucose-6-phosphate dehydrogenase deficiency in ecuadorian ethnic groups: a malaria perspective.Malaria journal · 2023Article
- Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study.Malaria journal · 2023Article
- Biology and epidemiology ofParasite epidemiology and control · 2023Review
- Article
- Is it time for Africa to adopt primaquine in the era of malaria control and elimination?Tropical medicine and health · 2022Review
- An Epidemiological Analysis of 28 Vivax Malaria Cases in Gimpo-si, Korea, 2020.The Korean journal of parasitology · 2021Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.